Dr. Irene Ghobrial who acts as the Assistant Professor of Medicine in the Bing Center for Waldenstromâ€™s Macroglobulinemia located at the Dana-Farber Cancer Institute has led the Phase 2 revision.
Online PR News – 05-June-2011 – – AEterna Zentaris Inc, a company developing a late-stage cancer drug, specialises in oncology and endocrinology. The company just announced on January 29th 2010, an article with the name â€śClinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstromâ€™s Macroglobulinemiaâ€ť. This report describes the results of using perifosine as a single agent for the treatment of Waldenstrom's Macroglobulinemia. This report will be appearing on February 1st 2010, in the journal of Clinical Cancer Research. The companyâ€™s oral inhibitor known as PI3K/AKT Pathway inhibitor is being under the investigation in the phase 3 trial. Waldenstromâ€™s Macroglobulinemia is a hematologic sickness in which the cells affected by cancer normally target the bone marrow.
Dr. Irene Ghobrial who acts as the Assistant Professor of Medicine in the Bing Center for Waldenstromâ€™s Macroglobulinemia located at the Dana-Farber Cancer Institute has led the Phase 2 revision. This study of phase 2 will be performed wherein 37 patients were examined with perifosine with a quantity of 150 mg daily for 6 cycles. Perifosine serves as a single agent which has the efficiency and promises to treat the patients who are affected by relapsed/refractory Waldenstromâ€™s Macroglobulinemia. This is clearly understandable from the comment posted by Dr. Ghobrial.
As per the statement of Juergen Engel, The president & the CEO of AEterna Zentaris, the results and evidence obtained from perifosine use are quite promising and have potential as a novel approach for the treatment of different types of cancer. They are now looking forward to the future development of a later-stage of this compound in Waldenstromâ€™s Macroglobulinemia and metastatic colon cancer and even for multiple myeloma. For this purpose perifosine has entered into an ongoing phase 3 trials. Make sure to follow our website for the latest news.